| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1177/1099800403252574 |
| P953 | full work available at URL | http://journals.sagepub.com/doi/pdf/10.1177/1099800403252574 |
| https://escholarship.org/content/qt1rp6g7c8/qt1rp6g7c8.pdf?t=oo8xdn | ||
| P698 | PubMed publication ID | 12698920 |
| P2093 | author name string | Heather Sands | |
| John L. Fahey | |||
| Adrian M. Casillas | |||
| Adeline M. Nyamathi | |||
| P2860 | cites work | Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections | Q44089771 |
| Surviving Ebola virus infection | Q44089831 | ||
| Fighting the Ebola virus | Q44090031 | ||
| Major Expansion of γδ T Lymphocytes following Cytomegalovirus Infection in Kidney Allograft Recipients | Q57323030 | ||
| Viral arthritis | Q71669900 | ||
| Development of a preventive vaccine for Ebola virus infection in primates | Q28140401 | ||
| Ebola virus can be effectively neutralized by antibody produced in natural human infection | Q30712477 | ||
| Recombinant human monoclonal antibodies to Ebola virus | Q31905799 | ||
| The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis | Q33724407 | ||
| Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein | Q33865376 | ||
| Immunization for Ebola virus infection | Q34065766 | ||
| Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit | Q34068502 | ||
| Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins | Q34085822 | ||
| Hemorrhagic fever viruses as biological weapons: medical and public health management | Q34126496 | ||
| Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. | Q34479873 | ||
| An introduction to Ebola: the virus and the disease | Q34492420 | ||
| Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee | Q34492427 | ||
| Patients infected with high-hazard viruses: scientific basis for infection control. | Q41108027 | ||
| Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro | Q42537833 | ||
| Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival | Q43513037 | ||
| Ebola takes a punch | Q44089525 | ||
| DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge | Q44089592 | ||
| Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit | Q44089694 | ||
| Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. | Q44089744 | ||
| Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. | Q44089749 | ||
| Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection | Q44089752 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | disease outbreak | Q3241045 |
| Orthoebolavirus zairense | Q10538943 | ||
| Ebola vaccine | Q3553092 | ||
| P304 | page(s) | 276-281 | |
| P577 | publication date | 2003-04-01 | |
| P1433 | published in | Biological Research for Nursing | Q4914964 |
| P1476 | title | Ebola virus: immune mechanisms of protection and vaccine development | |
| Ebola Virus: Immune Mechanisms of Protection and Vaccine Development | |||
| P478 | volume | 4 |
Search more.